Before you sell to, join or invest in NBO Pharma Inc.
MentionFox check on NBO Pharma Inc.: only 1 source on file so far (checked 7 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/nbo-pharma-inc-form-d-26000001
Check NBO Pharma Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
NBO Pharma Inc. filed a Form D with the Securities and Exchange Commission on 2026-01-22.
NBO Pharma Inc. filed a Form D notice of an exempt securities offering with the SEC on January 22, 2026. The filing reports $7.64M sold. Its industry group is Pharmaceuticals. It names Fredric Price (Executive Officer, Director), Robert Friedman (Director), Colin Foster (Director) (SEC Form D, January 22, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like NBO Pharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-01-22 · the record
Pitching, partnering or investing alongside them? See who really runs and owns NBO Pharma Inc.
Free to see. No signup.
More on the people and the money behind NBO Pharma Inc., from the filings we hold.
Paulson Investment Company, LLC received sales compensation on this raise and on 8 other raises we hold, nearest in date first:
Pharmaceuticals raises by companies based in New York, filed within 90 days of this one, largest first.
Get an email when NBO Pharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when NBO Pharma Inc. raises, hires or launches. No email unless you switch it on.
Watch NBO Pharma Inc. →Get the full cited report on NBO Pharma Inc.
What the filing shows about NBO Pharma Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on NBO Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives NBO Pharma Inc.'s address as 64 Quarry Lane, Bedford, NY 10506.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for NBO Pharma Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
NBO Pharma Inc. is a registered filer with the SEC (CIK 2103906) and has filed since 2026-01-22. 1 filing is on record, the latest on 2026-01-22.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
NBO Pharma Inc.'s Form D of 2026-01-22 names Fredric Price, Robert Friedman, Colin Foster and 1 more as its officers, directors or promoters.
Its new offerings report $7.64M sold across 1 offering, as its own filings state.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week. The dot is this raise, $7.64M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
NBO (acronym for Nasal Bioavailability of Octreotide) Pharma Inc. was incorporated in 2021 to develop a drug for the treatment of Idiopathic Intracranial Hypertension [IIH] for which no drugs are approved. We are re-purposing an existing orphan drug – octreotide acetate – with an Intranasal [IN] formulation. IN octreotide is undergoing clinical trials for IIH.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Fredric Price is named as Executive Officer and Director on the Form D that NBO Pharma Inc. filed with the SEC on 22 January 2026, one of 4 people that filing names.
Robert Friedman is named as Director on the Form D that NBO Pharma Inc. filed with the SEC on 22 January 2026, one of 4 people that filing names.
Colin Foster is named as Director on the Form D that NBO Pharma Inc. filed with the SEC on 22 January 2026, one of 4 people that filing names.
Bard Geesaman is named as Director on the Form D that NBO Pharma Inc. filed with the SEC on 22 January 2026, one of 4 people that filing names.
4 people named on the filing — 1 holding an executive role and 3 as directors only.
Named as of the 2026-01-22 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about NBO Pharma Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on NBO Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NBO Pharma Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist NBO Pharma Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind NBO Pharma Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-07 (nbopharma.com).
Each opens in a new tab, filled in for NBO Pharma Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/nbo-pharma-inc-form-d-26000001